Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €135.19 EUR
Change Today +5.51 / 4.25%
Volume 406.0
BAYA On Other Exchanges
Symbol
Exchange
OTC US
Xetra
OTC US
BrsaItaliana
Xetra
Mexico
Continuous
As of 10:51 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for bayer ag-sponsored adr (BAYA)

Year over year, Bayer AG has been able to grow revenues from €40.2B EUR to €42.2B EUR. Most impressively, the company has been able to reduce the percentage of sales devoted to cost of goods sold from 48.39% to 47.86%. This was a driver that led to a bottom line growth from €3.2B EUR to €3.4B EUR.
View Income Statement In U.S. Dollar
Currency in
Millions of Euros
As of:Dec 31
2011
Reclassified
EUR
Dec 31
2012
Restated
EUR
Dec 31
2013
Reclassified
EUR
Dec 31
2014
EUR
4 Year
Trend
Revenues36,528.039,741.040,157.042,239.0
TOTAL REVENUES36,528.039,741.040,157.042,239.0
Cost of Goods Sold17,975.019,070.019,433.020,217.0
GROSS PROFIT18,553.020,671.020,724.022,022.0
Selling General & Admin Expenses, Total11,007.012,237.012,195.012,996.0
R&D Expenses2,932.03,013.03,407.03,572.0
Other Operating Expenses42.0268.0-68.0-54.0
OTHER OPERATING EXPENSES, TOTAL13,981.015,518.015,534.016,514.0
OPERATING INCOME4,572.05,153.05,190.05,508.0
Interest Expense-898.0-743.0-656.0-693.0
Interest and Investment Income563.0491.0301.0337.0
NET INTEREST EXPENSE-335.0-252.0-355.0-356.0
Income (Loss) on Equity Investments-43.0-18.0-16.0-13.0
Currency Exchange Gains (Loss)-53.0-69.0-120.0-248.0
Other Non-Operating Income (Expenses)-17.0-18.0-14.0-45.0
EBT, EXCLUDING UNUSUAL ITEMS4,124.04,796.04,685.04,846.0
Merger & Restructuring Charges---379.0-163.0-93.0
Impairment of Goodwill-------173.0
Gain (Loss) on Sale of Investments-2.014.075.03.0
Gain (Loss) on Sale of Assets172.0214.0119.0143.0
Other Unusual Items, Total-931.0-1,469.0-509.0-201.0
Insurance Settlements--18.0--64.0
Legal Settlements-238.0-1,298.0-334.0-168.0
Other Unusual Items-731.0114.0-208.0-91.0
EBT, INCLUDING UNUSUAL ITEMS3,363.03,176.04,207.04,525.0
Income Tax Expense891.0723.01,021.01,082.0
Minority Interest in Earnings-2.0-50.03.0-17.0
Earnings from Continuing Operations2,472.02,453.03,186.03,443.0
NET INCOME2,470.02,403.03,189.03,426.0
NET INCOME TO COMMON INCLUDING EXTRA ITEMS2,470.02,403.03,189.03,426.0
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS2,470.02,403.03,189.03,426.0
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAYA:GR €135.19 EUR +5.51

BAYA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $70.77 USD -0.46
Amgen Inc $171.47 USD -1.27
Bristol-Myers Squibb Co $64.89 USD +0.23
GlaxoSmithKline PLC 1,375 GBp +46.00
Novo Nordisk A/S kr400.00 DKK +7.00
View Industry Companies
 

Industry Analysis

BAYA

Industry Average

Valuation BAYA Industry Range
Price/Earnings 33.5x
Price/Sales 2.5x
Price/Book 5.1x
Price/Cash Flow 33.5x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAYER AG-SPONSORED ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.